JB Pharmaceuticals posted a strong start to the fiscal year with a 14% year-on-year growth in net profit, reaching Rs. 202 crore for the quarter ended June 2025. The pharmaceutical firm attributed its performance to higher domestic formulation sales and strong traction in international markets. Revenue from operations rose to Rs. 950 crore, reflecting growing momentum across therapeutic categories.